NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Avilar Therapeutics

Avilar Therapeutics

Private
Waltham, MassachusettsHealthcare & Life Scienceshttps://avilar-tx.com/

Last Round

Seed

Feb 16, 2023

Total Funding Raised

$135M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Avilar Therapeutics is a biotechnology company that develops innovative extracellular protein degraders to target and eliminate disease-causing proteins from circulation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

extracellular protein degradationATACstargeted protein degradationTPDextracellular degradersundruggable targetsASGPR Targeting Chimerasprotein degradersdrug discovery platformsmall molecule therapeuticsliver targeting therapeuticspharma partnershipspreclinical biotechnologyASGPRMTAC platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Avilar Therapeutics Comparables

Compare Avilar Therapeutics with similar companies based on industry and business-model similarity.

Avilar Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Draupnir Bio
87%
Lycia Therapeutics
86%
GlycoEra
83%

Avilar Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedFeb 16, 2023
SeedNov 18, 2021

Avilar Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors increased 39% MoM, reaching 2.3K.

  • Feb 16, 2023

    $15M round with participation from RA Capital Management.

Avilar Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Avilar Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Avilar Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range24
Year Founded2020
Last FundingFeb 16, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.